Hämoblastosen - Myeloproliferative Erkrankungen -
Chronische myeloische Leukämie (CML) - Weiterführende Informationen

Leitlinien

www.dgho-onkopedia.de → Leitlinien (Hochhaus, 09/2009)

Studien

Studienübersicht unter www.kompetenznetz-leukaemie.de

Literatur

3. Hasford J et al: Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood online 2011; 118: 686–692
4. Baccarani M, Cortes J, Pane F et al. Chronic Myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009; 27: 6041-6051
5. Soverini S et al: BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood 2011; 118: 1208–15
6. Preudhomme C, Guilhot J, Nicolini FE et al. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med 2010; 363: 2511–21